Li Ying, Miao Lan, Guo Rongjuan, He Lijuan, Sun Mingqian, Pan Yinghong, Lin Li, Ren Junguo, Liu Jianxun
Beijing Key Laboratory of Pharmacology of Chinese Materia Region, Institute of Basic Medical Sciences, Xiyuan Hospital, China Academy of Chinese Medical Sciences, National clinical research center of cardiovascular disease of traditional Chinese Medicine, Beijing, 100000, China.
Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, 100078, China.
J Proteomics. 2023 Apr 15;277:104850. doi: 10.1016/j.jprot.2023.104850. Epub 2023 Feb 20.
Buyang Huanwu Decoction (BYHW) contains chemical components such as ligustrazine, oxypaeoniflora, chlorogenic acid, and others. To explore the neuroprotective effect and potential target protein of BYHW in cerebral infarction (CI). A double-blind, randomized controlled trial was established and patients with CI were divided into the BYHW group (n = 35) and the control group (n = 30). To evaluate the efficacy by TCM syndrome score and clinical indicators, and to explore the changes of serum proteins by proteomics technology, so as to explore the mechanism of BYHW and potential target proteins. The study found that compared with the control group, the TCM syndrome score, including Deficiency of Vital Energy (DVE), Blood Stasis (BS), and NIHSS in the BYHW group decreased significantly (p < 0.05), and the Barthel Index (BI) score was significantly higher. A total of 99 differential regulatory proteins were identified by proteomics, which act on lipids and atherosclerosis, complement and coagulation cascade, and TNF-α signaling pathway. In addition, Elisa verified the results of proteomics and found that BYHW can reduce the neurological impairments focus on IL-1β, IL-6, TNF-α, MCP-1, MMP-9, and PAI-1. Significance: In this study, quantitative proteomics was used in combination with liquid chromatography-mass spectrometry (LC-MS/MS) to study the therapeutic effect of BYHW on cerebral infarction (CI) and potential changes in serum proteomics. In addition, the public proteomics database was used for bioinformatics analysis, and Elisa experiment verified the results of proteomics, further clarifying the potential protection mechanism of BYHW on CI.
补阳还五汤（BYHW）含有川芎嗪、芍药苷、绿原酸等化学成分。为探讨补阳还五汤对脑梗死（CI）的神经保护作用及潜在靶蛋白。建立了一项双盲、随机对照试验，将CI患者分为补阳还五汤组（n = 35）和对照组（n = 30）。通过中医证候评分和临床指标评估疗效，采用蛋白质组学技术探索血清蛋白的变化，以探讨补阳还五汤的作用机制及潜在靶蛋白。研究发现，与对照组相比，补阳还五汤组的中医证候评分，包括气虚（DVE）、血瘀（BS）和美国国立卫生研究院卒中量表（NIHSS）显著降低（p < 0.05），巴氏指数（BI）评分显著升高。通过蛋白质组学共鉴定出99种差异调节蛋白，它们作用于脂质与动脉粥样硬化、补体和凝血级联反应以及肿瘤坏死因子-α信号通路。此外，酶联免疫吸附测定（ELISA）验证了蛋白质组学的结果，发现补阳还五汤可减轻以白细胞介素-1β、白细胞介素-6、肿瘤坏死因子-α、单核细胞趋化蛋白-1、基质金属蛋白酶-9和纤溶酶原激活物抑制剂-1为重点的神经损伤。意义：本研究采用定量蛋白质组学结合液相色谱-质谱联用（LC-MS/MS）技术研究补阳还五汤对脑梗死（CI）的治疗作用及血清蛋白质组学的潜在变化。此外，利用公共蛋白质组学数据库进行生物信息学分析，ELISA实验验证了蛋白质组学结果，进一步阐明了补阳还五汤对CI的潜在保护机制。
